Latest Regulatory News

Klevo Rewards Limited’s subsidiary Fly Wallet has secured key Mastercard compliance and earned over AUD 550,000 in incentives, marking a significant step in its payments platform evolution.

Tungsten Mining NL has launched a Project Economic Evaluation to explore accelerated development of its Watershed Project, leveraging existing approvals to potentially fast-track production in a tightening tungsten market.

The US Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, a move that could significantly benefit Neuren Pharmaceuticals as it advances its rare disease drug candidates.

Santana Minerals has secured a clear statutory timeline for the Bendigo-Ophir Gold Project fast-track approval, with a decision expected by late October 2026. The appointment of a seven-member Expert Panel marks a significant step in the project's regulatory journey.

Global Uranium and Enrichment Ltd shares have been suspended from the ASX following Federal Court approval of a scheme of arrangement for acquisition by Snow Lake Resources Ltd.

RPMGlobal Holdings Limited shares will be suspended from the ASX following Federal Court approval of its acquisition by a Caterpillar subsidiary, marking a significant ownership change.

Codeifai Limited has raised $1.1 million through a share placement that coincided with a sharp increase in its share price, confirming full compliance with ASX disclosure rules following a detailed inquiry.

Lake Resources has clarified its latest cash flow report, highlighting $666k spent on environmental and power solution explorations while advancing key regulatory approvals for its Kachi lithium project. The company maintains a robust liquidity position and benefits from new technology partnerships aimed at reducing costs.

Australian Critical Minerals Ltd has updated its Flint Gold-Silver Project presentation, confirming drill readiness with permits and funding secured for an initial diamond drilling program in Peru’s prolific epithermal belt.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Evolution Trustees has appointed LDR Capital as the new manager of Elanor Commercial Property Fund following the termination of previous management agreements with Elanor Asset Services.

Elanor Commercial Property Fund members have voted to replace Elanor Funds Management Limited with Evolution Trustees Limited as the responsible entity, marking a significant governance shift now officially recorded by ASIC.